Spyre Therapeutics (SYRE) Total Debt (2023 - 2025)
Historic Total Debt for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $11.0 million.
- Spyre Therapeutics' Total Debt fell 5545.68% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 5545.68%. This contributed to the annual value of $25.1 million for FY2024, which is 170431.65% up from last year.
- As of Q3 2025, Spyre Therapeutics' Total Debt stood at $11.0 million, which was down 5545.68% from $59.9 million recorded in Q2 2025.
- Spyre Therapeutics' Total Debt's 5-year high stood at $164.4 million during Q2 2023, with a 5-year trough of $1.4 million in Q4 2023.
- Its 3-year average for Total Debt is $34.2 million, with a median of $17.9 million in 2024.
- Per our database at Business Quant, Spyre Therapeutics' Total Debt plummeted by 9839.4% in 2024 and then soared by 216893.94% in 2025.
- Over the past 3 years, Spyre Therapeutics' Total Debt (Quarter) stood at $1.4 million in 2023, then surged by 1704.32% to $25.1 million in 2024, then plummeted by 56.06% to $11.0 million in 2025.
- Its last three reported values are $11.0 million in Q3 2025, $59.9 million for Q2 2025, and $42.8 million during Q1 2025.